Main clinical and laboratory characteristics of the external validation cohort
| N | 329 |
| Median age, y (range) | 53 (16-92) |
| Male/female, n (%) | 113/216 (34/66)* |
| Median leukocyte count, × 109/L (5th-95th percentile) | 8.95 (5.59-15.7) |
| Median hemoglobin, g/dL (5th-95th percentile) | 14.0 (10.6-16.5) |
| Median platelets, × 109/L (5th-95th percentile) | 689 (456-1321)* |
| CV risk factors, n (%) | 138 (42)* |
| JAK2V617F-positive, n (%) | 206 (63) |
| Previous thrombosis, n (%) | 81 (25) |
| Arterial, n (%) | 52 (16) |
| Venous, n (%) | 29 (9) |
| Median follow-up, y (range) | 5.0 (0.4-25)* |
| Treatments, n (%) | |
| Cytoreductive therapy | 128 (61)* |
| Aspirin use | 292 (89)* |
| N | 329 |
| Median age, y (range) | 53 (16-92) |
| Male/female, n (%) | 113/216 (34/66)* |
| Median leukocyte count, × 109/L (5th-95th percentile) | 8.95 (5.59-15.7) |
| Median hemoglobin, g/dL (5th-95th percentile) | 14.0 (10.6-16.5) |
| Median platelets, × 109/L (5th-95th percentile) | 689 (456-1321)* |
| CV risk factors, n (%) | 138 (42)* |
| JAK2V617F-positive, n (%) | 206 (63) |
| Previous thrombosis, n (%) | 81 (25) |
| Arterial, n (%) | 52 (16) |
| Venous, n (%) | 29 (9) |
| Median follow-up, y (range) | 5.0 (0.4-25)* |
| Treatments, n (%) | |
| Cytoreductive therapy | 128 (61)* |
| Aspirin use | 292 (89)* |
CV indicates cardiovascular.
Variables significantly different compared with training set (P < .05).